Literature DB >> 36074261

Renal lesion characterization: clinical utility of single-phase dual-energy CT compared to MRI and dual-phase single-energy CT.

Ali Pourvaziri1, Amirkasra Mojtahed2, Peter F Hahn2, Michael S Gee2, Avinash Kambadakone2, Dushyant V Sahani3.   

Abstract

OBJECTIVES: To assess the impact of dual-energy CT (DECT) utilization in practice by measuring the readers' confidence, the need for additional image requests, and diagnostic performance in renal lesion assessment, compared to single-energy CT (SECT) using contrast-enhanced MRI to establish the reference standard.
MATERIALS AND METHODS: Sixty-nine patients (M/F = 47/22) who underwent a dual-phase renal SECT (n = 34) or DECT (n = 35) and had a contrast-enhanced MRI within 180 days were retrospectively collected. Three radiologists assessed images on different sessions (SECT, DECT, and MRI) for (1) likely diagnosis (enhancing/non-enhancing); (2) diagnostic confidence (5-point Likert scale); (3) need for additional imaging test (yes/no); and (4) need for follow-up imaging (yes/no). Diagnostic accuracy was compared using AUC; p value < 0.05 was considered significant.
RESULTS: One hundred fifty-six lesions consisting of 18% enhancing (n = 28/156, mean size: 30.37 mm, range: 9.9-94 mm) and 82% non-enhancing (n = 128/156, mean size: 23.91 mm, range: 5.0-94.2 mm) were included. The confidence level was significantly lower for SECT than their MRI (4.50 vs. 4.80, p value < 0.05) but not significantly different for DECT and the corresponding MRI (4.78 vs. 4.78, p > 0.05). There were significantly more requests for additional imaging in the SECT session than the corresponding MRI (20% vs. 4%), which was not significantly different between DECT and their MRI counterpart session (5.7% vs. 4.9%). Inter-reader agreement was almost perfect for DECT and MRI (kappa: 0.8-1) and substantial in SECT sessions (kappa: 0.6-0.8) with comparable diagnostic accuracy between SECT, DECT, and MRI (p value > 0.05).
CONCLUSION: Single-phase DECT allows confident and reproducible characterization of renal masses with fewer recommendation for additional and follow-up imaging tests than dual-phase SECT and a performance similar to MRI. KEY POINTS: • DECT utilization leads to similar additional image requests to MRI (5.7% vs. 4.9%, p value > 0.05), whereas single-energy CT utilization leads to significantly higher image requests (20% vs. 4%, p value < 0.05). • DECT and MRI utilization bring highly reproducible results with almost perfect inter-reader agreement (kappa: 0.8-1), better than the inter-reader agreement in SECT utilization (kappa: 0.6-0.8). • Readers' confidence was not significantly altered between DECT and their MRI readout session (p value > 0.05). In contrast, confidence in the diagnosis was significantly lower in the SECT session than their MRI readout (p value < 0.05).
© 2022. The Author(s), under exclusive licence to European Society of Radiology.

Entities:  

Keywords:  Computed tomography; Diagnostic accuracy; Diagnostic confidence; Dual-energy CT scan; MRI Renal neoplasm

Year:  2022        PMID: 36074261     DOI: 10.1007/s00330-022-09106-6

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   7.034


  29 in total

1.  Renal cyst pseudoenhancement: evaluation with an anthropomorphic body CT phantom.

Authors:  Bernard A Birnbaum; Daniel D Maki; Dev P Chakraborty; Jill E Jacobs; James S Babb
Journal:  Radiology       Date:  2002-10       Impact factor: 11.105

2.  Multi-detector row CT attenuation measurements: assessment of intra- and interscanner variability with an anthropomorphic body CT phantom.

Authors:  Bernard A Birnbaum; Nicole Hindman; Julie Lee; James S Babb
Journal:  Radiology       Date:  2007-01       Impact factor: 11.105

3.  Diagnostic value of MR imaging in comparison to CT in the detection and differential diagnosis of renal masses: ROC analysis.

Authors:  B P Kreft; H Müller-Miny; T Sommer; A Steudel; M Vahlensieck; D Novak; B G Müller; H H Schild
Journal:  Eur Radiol       Date:  1997       Impact factor: 5.315

4.  Enhancement Threshold of Small (< 4 cm) Solid Renal Masses on CT.

Authors:  Fawaz Al Harbi; Leila Tabatabaeefar; Michael A Jewett; Anthony Finelli; Martin O'Malley; Mostafa Atri
Journal:  AJR Am J Roentgenol       Date:  2016-03       Impact factor: 3.959

5.  Role of MRI in indeterminate renal mass: diagnostic accuracy and impact on clinical decision making.

Authors:  Taekmin Kwon; In Gab Jeong; Sangjun Yoo; JungBok Lee; Sungwoo Hong; Dalsan You; Jun Hyuk Hong; Hanjong Ahn; Choung-Soo Kim
Journal:  Int Urol Nephrol       Date:  2015-02-14       Impact factor: 2.370

6.  Rising incidence of small renal masses: a need to reassess treatment effect.

Authors:  John M Hollingsworth; David C Miller; Stephanie Daignault; Brent K Hollenbeck
Journal:  J Natl Cancer Inst       Date:  2006-09-20       Impact factor: 13.506

Review 7.  Increased incidence of serendipitously discovered renal cell carcinoma.

Authors:  M Jayson; H Sanders
Journal:  Urology       Date:  1998-02       Impact factor: 2.649

8.  Managing incidental findings on abdominal CT: white paper of the ACR incidental findings committee.

Authors:  Lincoln L Berland; Stuart G Silverman; Richard M Gore; William W Mayo-Smith; Alec J Megibow; Judy Yee; James A Brink; Mark E Baker; Michael P Federle; W Dennis Foley; Isaac R Francis; Brian R Herts; Gary M Israel; Glenn Krinsky; Joel F Platt; William P Shuman; Andrew J Taylor
Journal:  J Am Coll Radiol       Date:  2010-10       Impact factor: 5.532

9.  Evaluation of cystic renal masses: comparison of CT and MR imaging by using the Bosniak classification system.

Authors:  Gary M Israel; Nicole Hindman; Morton A Bosniak
Journal:  Radiology       Date:  2004-05       Impact factor: 11.105

10.  Comparison of MDCT, MRI and MRI with diffusion-weighted imaging in evaluation of focal renal lesions: The defender, challenger, and winner!

Authors:  Ankur Goyal; Raju Sharma; Ashu S Bhalla; Shivanand Gamanagatti; Amlesh Seth
Journal:  Indian J Radiol Imaging       Date:  2018 Jan-Mar
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.